Heartflow (NASDAQ:HTFL) Insider Sells 9,219 Shares

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 9,219 shares of Heartflow stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $41.23, for a total transaction of $380,099.37. Following the completion of the transaction, the insider owned 86,459 shares of the company’s stock, valued at $3,564,704.57. This represents a 9.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heartflow Price Performance

Shares of NASDAQ:HTFL traded up $0.30 during trading on Wednesday, hitting $45.53. 2,938,828 shares of the company were exchanged, compared to its average volume of 1,751,769. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $47.23. The stock has a 50 day moving average of $30.00 and a 200 day moving average of $28.05. The company has a market cap of $3.96 billion and a PE ratio of -24.88.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The company had revenue of $64.08 million during the quarter. The company’s revenue was up 47.7% compared to the same quarter last year. Sell-side analysts forecast that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HTFL. JPMorgan Chase & Co. upped their price target on Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Piper Sandler restated an “overweight” rating and issued a $45.00 price objective (up from $38.00) on shares of Heartflow in a research report on Friday, August 14th. William Blair assumed coverage on shares of Heartflow in a research note on Monday, May 4th. They set an “outperform” rating for the company. Weiss Ratings raised shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Finally, Morgan Stanley increased their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.43.

Hedge Funds Weigh In On Heartflow

A number of institutional investors have recently added to or reduced their stakes in HTFL. TrueMark Investments LLC increased its position in shares of Heartflow by 1.4% in the first quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock worth $654,000 after purchasing an additional 379 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow in the fourth quarter valued at approximately $27,000. Strs Ohio lifted its position in Heartflow by 35.3% during the first quarter. Strs Ohio now owns 4,600 shares of the company’s stock valued at $112,000 after purchasing an additional 1,200 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Heartflow in the 4th quarter worth approximately $45,000. Finally, Legal & General Group Plc purchased a new position in Heartflow in the 3rd quarter worth approximately $59,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.